Preclinical PERCIST and 25% of SUV_max Threshold: Precision Imaging of Response to Therapy in Co-clinical ¹⁸F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.

ABSTRACT: Numerous recent works highlight the limited utility of established tumor cell lines in recapitulating the heterogeneity of tumors in patients. More realistic preclinical cancer models are thought to be provided by transplantable, patient-derived xenografts (PDXs). The inter- and intratumor heterogeneity of PDXs, however, presents several challenges in developing optimal quantitative pipelines to assess response to therapy. The objective of this work was to develop and optimize image metrics for ¹⁸F-FDG PET to assess response to combination docetaxel and carboplatin therapy in a co-clinical trial involving triple-negative breast cancer PDXs. We characterized the reproducibility of standardized uptake value (SUV) metrics to assess response to therapy, and we optimized a preclinica

SUBMITTER: Savaikar MA 

PROVIDER: S-EPMC7262224 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature